Funding Opportunities

We offer funding for Alzheimer's drug discovery and preclinical development, clinical trials, and biomarker development research. Visit our Research Priorities for specific information about our interests.

Our funding is open to:
• Researchers, clinicians, and postdoctoral fellows
• Working in academia and biotechnology companies
• Based in the U.S. and worldwide

The ADDF currently accepts grant proposals through five RFPs. (For returning grantees, we accept proposals for follow-on funding and renewals.)

 


Alzheimer's Combination Therapy Opportunities (ACTO) Program

Purpose:

Jointly funded by the ADDF, Alzheimer's Association, and the UK's Alzheimer's Society, the ACTO program supports biomarker-based combination trials testing repurposed drug combinations from Phase 1 through Phase 2 proof of concept.

Next Deadline:

Letter of Intent: May 20, 2016
Full Application: August 10, 2016

Submit Online:

Submit LOIs and Applications through Alzheimer's Association Portal

Review RFP (PDF)

 


Preclinical Drug Discovery RFP

Purpose:

Seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, related dementias and cognitive aging.

Avg. Duration:

1-2 years

Avg. Award:

$150,000-$600,000

Next Deadlines: (4/year)

Letter of Intent: May 13, 2016
Invited Full Proposal: June 3, 2016

Review RFP (PDF)

CLICK HERE TO APPLY

 


Program to Accelerate Clinical Trials (PACT)

Purpose:

Designed to increase the number of novel and repurposed treatments tested in humans for Alzheimer's disease, related dementias and cognitive aging. It funds biomarker-based, proof-of-concept pilot clinical trials for Alzheimer's, as well as Phase 1 safety testing and IND-enabling studies to accelerate new drugs into trials.

Avg. Duration:

Varies

Avg. Award:

Up to $3 million

Next Deadlines: (4/year)

Letter of Intent: May 13, 2016
Invited Full Proposal: June 3, 2016

Review RFP (PDF)

CLICK HERE TO APPLY

 


Accelerating Drug Discovery for Frontotemporal Degeneration RFP

Purpose:

Accelerates drug discovery programs and biomarker development for frontotemporal degeneration and is funded in partnership with The Association for Frontotemporal Degeneration (AFTD).

Avg. Duration:

1 year

Avg. Award:

$100,000-$150,000

Next Deadline: (1/year)

Letter of Intent: August 12, 2016
Full Application: September 2, 2016

Review RFP (PDF)

CLICK HERE TO APPLY

 


ADDF/NIH RFP

Purpose:

The RFP supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.

Avg. Duration:

1-2 years

Avg. Award:

Varies

Next Deadline: (Rolling)

Proposals accepted on a rolling basis

Review RFP (PDF)

CLICK HERE TO APPLY
Print